Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.73
KBIO's Cash to Debt is ranked lower than
68% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. KBIO: 2.73 )
Ranked among companies with meaningful Cash to Debt only.
KBIO' s 10-Year Cash to Debt Range
Min: 2.07  Med: 6.82 Max: No Debt
Current: 2.73
F-Score: 3
Z-Score: -14.52
M-Score: -4.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -132.32
KBIO's ROE (%) is ranked lower than
86% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. KBIO: -132.32 )
Ranked among companies with meaningful ROE (%) only.
KBIO' s 10-Year ROE (%) Range
Min: -89.25  Med: -89.25 Max: -89.25
Current: -132.32
ROA (%) -78.82
KBIO's ROA (%) is ranked lower than
79% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. KBIO: -78.82 )
Ranked among companies with meaningful ROA (%) only.
KBIO' s 10-Year ROA (%) Range
Min: -107.14  Med: -71.86 Max: -23.07
Current: -78.82
-107.14
-23.07
ROC (Joel Greenblatt) (%) -8026.91
KBIO's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. KBIO: -8026.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16150.99  Med: -8881.25 Max: -1061.83
Current: -8026.91
-16150.99
-1061.83
Revenue Growth (3Y)(%) -100.00
KBIO's Revenue Growth (3Y)(%) is ranked lower than
100% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. KBIO: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KBIO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: -95.1
Current: -100
EBITDA Growth (3Y)(%) 8.60
KBIO's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. KBIO: 8.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KBIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -18.90 Max: 8.6
Current: 8.6
0
8.6
» KBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

KBIO Guru Trades in Q3 2014

PRIMECAP Management 4,475,700 sh (unchged)
First Eagle Investment 1,746,591 sh (unchged)
Jim Simons 126,866 sh (-48.28%)
» More
Q4 2014

KBIO Guru Trades in Q4 2014

Jim Simons 264,900 sh (+108.80%)
First Eagle Investment 1,746,591 sh (unchged)
PRIMECAP Management 4,475,700 sh (unchged)
First Eagle Investment 1,746,591 sh (unchged)
» More
Q1 2015

KBIO Guru Trades in Q1 2015

Jim Simons 350,194 sh (+32.20%)
First Eagle Investment Sold Out
PRIMECAP Management 4,352,300 sh (-2.76%)
» More
Q2 2015

KBIO Guru Trades in Q2 2015

Jim Simons 564,673 sh (-79.84%)
PRIMECAP Management 4,327,600 sh (-87.57%)
» More
» Details

Insider Trades

Latest Guru Trades with KBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.81
KBIO's P/B is ranked higher than
96% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. KBIO: 0.81 )
Ranked among companies with meaningful P/B only.
KBIO' s 10-Year P/B Range
Min: 0.12  Med: 1.14 Max: 3.68
Current: 0.81
0.12
3.68
EV-to-EBIT 0.18
KBIO's EV-to-EBIT is ranked higher than
97% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. KBIO: 0.18 )
Ranked among companies with meaningful EV-to-EBIT only.
KBIO' s 10-Year EV-to-EBIT Range
Min: -2.7  Med: -0.10 Max: 1.4
Current: 0.18
-2.7
1.4
Current Ratio 1.71
KBIO's Current Ratio is ranked lower than
78% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. KBIO: 1.71 )
Ranked among companies with meaningful Current Ratio only.
KBIO' s 10-Year Current Ratio Range
Min: 1.71  Med: 5.14 Max: 11.14
Current: 1.71
1.71
11.14
Quick Ratio 1.71
KBIO's Quick Ratio is ranked lower than
74% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. KBIO: 1.71 )
Ranked among companies with meaningful Quick Ratio only.
KBIO' s 10-Year Quick Ratio Range
Min: 1.71  Med: 5.14 Max: 11.14
Current: 1.71
1.71
11.14

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.96
KBIO's Price/Net Cash is ranked higher than
98% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. KBIO: 0.96 )
Ranked among companies with meaningful Price/Net Cash only.
KBIO' s 10-Year Price/Net Cash Range
Min: 1.12  Med: 2.23 Max: 3.11
Current: 0.96
1.12
3.11
Price/Net Current Asset Value 0.87
KBIO's Price/Net Current Asset Value is ranked higher than
98% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. KBIO: 0.87 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KBIO' s 10-Year Price/Net Current Asset Value Range
Min: 1.05  Med: 2.14 Max: 2.94
Current: 0.87
1.05
2.94
Price/Tangible Book 0.80
KBIO's Price/Tangible Book is ranked higher than
97% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. KBIO: 0.80 )
Ranked among companies with meaningful Price/Tangible Book only.
KBIO' s 10-Year Price/Tangible Book Range
Min: 1  Med: 2.07 Max: 2.87
Current: 0.8
1
2.87
Earnings Yield (Greenblatt) (%) 537.96
KBIO's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. KBIO: 537.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KBIO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 69  Med: 87.05 Max: 16466.4
Current: 537.96
69
16466.4

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 10 12
EPS($) -1.00 -2.26
EPS without NRI($) -1.00 -2.26

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0KB1.Germany,
KaloBios Pharmaceuticals Inc. was incorporated on March 15, 2000. On February 5, 2013 the Company closed its initial public offering. The Company is a biopharmaceutical company engaged on the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families. With Humaneered antibody technology, the Company produced a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a clinical focus on respiratory diseases and cancer. Humaneered antibodies have tested clinically in over 250 patients with no evidence of immunogenicity. The Company identifies and develops products that treat multiple indications through proof-of-concept studies. The Company has advanced three antibodies to the clinical development stage: KB001-A, for the treatment of Pa VAP; KB004, for hematologic malignancies; and KB003, for severe asthma. KB001-A, is a Humaneered, recombinant, PEGylated, anti-Pseudomonas PcrV high-affinity Fab antibody that is being developed for the prevention and treatment of infections by Pa, a gram negative bacteria that can cause pneumonia in mechanically ventilated patients and chronic respiratory infections in individuals with CF. KB004 is a Humaneered, monoclonal antibody in which the carbohydrate chains lack fucose, thereby enhancing the targeted cell-killing activity of the antibody. KB003 is a Humaneered, recombinant monoclonal antibody that targets and neutralizes human granulocyte macrophage colony-stimulating factor, or GM-CSF, with potential for use in inflammatory, autoimmune and other indications. Humaneered technology platform addresses issues of therapeutic antibody engineering and down-stream processing issues. The Humaneered technology is a method for converting antibodies into engineered human antibodies designed for therapeutic use, particularly for chronic conditions. The technology is designed to produce antibodies that have specificity and affinity for their target antigen, low propensity for aggregation, and a long-term stability. KB001-A, KB003, and KB004 are all Humaneered antibodies or antibody fragments. The Company currently has a collaboration with Sanofi for the development of KB001-A, and have licensed its Humaneered technology non-exclusively to Novartis and also in-licensed certain rights from, among others, UCSF and LICR. The Company owns 12 issued U.S. patents, with another issued U.S. patent owned jointly with a third party. It has an exclusive license to seven U.S. patents and owns 49 issued foreign patents. The Company's competitors include pharmaceutical companies, biotechnology companies, academic institutions, and other research organizations. The Company also competes with Valneva, MedImmune, Micromet along with Nycomed among others.
» More Articles for KBIO

Headlines

Articles On GuruFocus.com

More From Other Websites
KALOBIOS PHARMACEUTICALS INC Financials Aug 21 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 10 2015
KaloBios Reports Second Quarter Financial Results and Provides Clinical Update Aug 10 2015
Biotech Sector Review Aug 04 2015
KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with... Jul 29 2015
KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement Jul 29 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Material Modification to Rights of Security... Jul 13 2015
KaloBios Announces Shareholders and Board of Directors Approval of Reverse Stock Split Jul 13 2015
Edited Transcript of KBIO presentation 23-Jun-15 2:30pm GMT Jun 26 2015
KaloBios to Present at the JMP Securities Life Sciences Conference Jun 17 2015
Adamas (ADMS) Worth Watching: Stock Moves 5.5% Higher - Tale of the Tape Jun 11 2015
Corium International (CORI) in Focus: Stock Rises 7.3% - Tale of the Tape Jun 08 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 01 2015
KaloBios Appoints Ronald A. Martell Executive Chairman May 28 2015
5 Stocks Under $10 Triggering Breakout Trades May 28 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 11 2015
KaloBios Reports First Quarter 2015 Financial Results May 11 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 24 2015
KaloBios Elects Ronald A. Martell to Board of Directors Apr 22 2015
KaloBios to Present at the 14th Annual Needham Healthcare Conference Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK